Research Reports

Key takeaways

Nathan Jorgensen, Ph.D., CFO, resigning effective May 8, 2026, to pursue new opportunity, not due to disagreement.

Robin Swartz appointed principal financial officer and treasurer effective May 8, 2026.

Amy Quinlan appointed principal accounting officer effective May 8, 2026.

Swartz has extensive internal experience at Voyager since 2021 and prior senior roles at Sanofi Genzyme.

Quinlan joined Voyager as VP Finance in January 2025, previously at Vor Biopharma and Tetraphase.

No family relationships or Item 404(a) disclosable transactions for Swartz or Quinlan.

Full analysis

The resignation of CFO Nathan Jorgensen effective May 8, 2026, is stated not to result from any disagreement, indicating an orderly transition. The board promptly appointed internal executives Robin Swartz and Amy Quinlan to key financial roles effective the same date, minimizing disruption. Swartz's long tenure at Voyager in operations, business, and prior financial roles, plus her Genzyme background, positions her for continuity. Quinlan's recent finance leadership adds depth. No related party issues or material transactions enhance transparency for investors.

VYGR · Voyager Therapeutics, Inc.

Summary

Key takeaways

Full analysis